中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2014年
33期
2566-2569
,共4页
陈骏%席玮%武贝%余辉%陈世晞
陳駿%席瑋%武貝%餘輝%陳世晞
진준%석위%무패%여휘%진세희
肝肿瘤%放射学,介入性%门静脉
肝腫瘤%放射學,介入性%門靜脈
간종류%방사학,개입성%문정맥
Liver neoplasms%Radiology,interventional%Portal vein
目的 探讨索拉非尼联合经导管肝动脉化疗栓塞(TACE)治疗肝癌伴门静脉癌栓(PVTT)的价值.方法 回顾性分析江苏省肿瘤医院2008年9月至2013年8月44例经TACE治疗肝癌伴PVTT病例,分为治疗组21例、对照组23例.治疗组除接受TACE治疗外,还在治疗前7d或治疗后14 d内开始每日2次口服0.4g索拉非尼.对照组只给予TACE治疗.随访观察指标包括疾病控制率(DCR)、总生存时间(OS)、疾病进展时间(TTP)、不良反应.结果 治疗组接受TACE治疗的次数多于对照组[(2.5±1.1)vs(1.8±1.1)次,P=0.019].术后3、6、9、12个月治疗组疾病控制率皆大于对照组,分别是81.0％比26.1％,47.6％比0,19.0％比0,4.8％比0,差异均有统计学意义(均P＜0.05).治疗组和对照组的中位OS分别是(252 ±32)和(123±18) d(P =0.001),中位TTP分别是(187±16)和(71±8)d(P =0.000).治疗组手足皮肤反应和腹泻发生率大于对照组,分别是90.5％比0(P =0.000)和66.7％比8.7％ (P =0.000).结论 索拉非尼可以延长TACE治疗肝癌伴PVTT患者的OS和TTP.
目的 探討索拉非尼聯閤經導管肝動脈化療栓塞(TACE)治療肝癌伴門靜脈癌栓(PVTT)的價值.方法 迴顧性分析江囌省腫瘤醫院2008年9月至2013年8月44例經TACE治療肝癌伴PVTT病例,分為治療組21例、對照組23例.治療組除接受TACE治療外,還在治療前7d或治療後14 d內開始每日2次口服0.4g索拉非尼.對照組隻給予TACE治療.隨訪觀察指標包括疾病控製率(DCR)、總生存時間(OS)、疾病進展時間(TTP)、不良反應.結果 治療組接受TACE治療的次數多于對照組[(2.5±1.1)vs(1.8±1.1)次,P=0.019].術後3、6、9、12箇月治療組疾病控製率皆大于對照組,分彆是81.0％比26.1％,47.6％比0,19.0％比0,4.8％比0,差異均有統計學意義(均P＜0.05).治療組和對照組的中位OS分彆是(252 ±32)和(123±18) d(P =0.001),中位TTP分彆是(187±16)和(71±8)d(P =0.000).治療組手足皮膚反應和腹瀉髮生率大于對照組,分彆是90.5％比0(P =0.000)和66.7％比8.7％ (P =0.000).結論 索拉非尼可以延長TACE治療肝癌伴PVTT患者的OS和TTP.
목적 탐토색랍비니연합경도관간동맥화료전새(TACE)치료간암반문정맥암전(PVTT)적개치.방법 회고성분석강소성종류의원2008년9월지2013년8월44례경TACE치료간암반PVTT병례,분위치료조21례、대조조23례.치료조제접수TACE치료외,환재치료전7d혹치료후14 d내개시매일2차구복0.4g색랍비니.대조조지급여TACE치료.수방관찰지표포괄질병공제솔(DCR)、총생존시간(OS)、질병진전시간(TTP)、불량반응.결과 치료조접수TACE치료적차수다우대조조[(2.5±1.1)vs(1.8±1.1)차,P=0.019].술후3、6、9、12개월치료조질병공제솔개대우대조조,분별시81.0％비26.1％,47.6％비0,19.0％비0,4.8％비0,차이균유통계학의의(균P＜0.05).치료조화대조조적중위OS분별시(252 ±32)화(123±18) d(P =0.001),중위TTP분별시(187±16)화(71±8)d(P =0.000).치료조수족피부반응화복사발생솔대우대조조,분별시90.5％비0(P =0.000)화66.7％비8.7％ (P =0.000).결론 색랍비니가이연장TACE치료간암반PVTT환자적OS화TTP.
Objective To investigate the efficacy of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.Methods A total of forty four patients of hepatocellular carcinoma with portal vein tumor thrombosis were retrospectively analyzed.There were twenty one patients in the treatment group,and the patients took oral 0.4 g sorafenib twice a day 7 days before or 14 days after TACE.Twenty three patients of control group were treated by TACE without sorafenib.Disease control rate (DCR),overall survival (OS),time to tumor progression (TTP) and side effects were followed up.Results The times of TACE in the treatment group was more than that in the control group (2.5 ± 1.1 vs 1.8 ± 1.1,P =0.019).DCR of the treatment group and the control group were 81.0％ vs26.1％,47.6％ vs0,19.0 vs0,and4.8％ vs0,3,6,9,and 12 months after TACE respectively,and the DCR of the treatment group were significantly higher than that of control group (P ＜ 0.05).The median OS of the treatment group and the control group were (252 ± 32)d and (123 ± 18) d (P =0.001) respectively.The median TTP of the treatment group and the control group were (187 ± 16) d and (71 ± 8) d (P =0.000) respectively.Hand foot skin reaction and diarrhea of the treatment group and the control group were 90.5％ vs 0 (P =0.000) and 66.7％ vs 8.7％ (P =0.000)respectively.Conclusion Sorafenib is efficacious,and may prolong OS and TTP in hepatocellular carcinoma with PVTT treated by TACE.
